| Literature DB >> 35631574 |
Álvaro Javier Feliz Morel1, Anida Hasanovic1, Aurélie Morin2, Chloé Prunier3, Virginie Magnone1, Kevin Lebrigand1, Amaury Aouad1, Sarah Cogoluegnes1, Judith Favier2, Claude Pasquier4, Isabelle Mus-Veteau1.
Abstract
Despite the development of new therapeutic strategies, cancer remains one of the leading causes of mortality worldwide. One of the current major challenges is the resistance of cancers to chemotherapy treatments inducing metastases and relapse of the tumor. The Hedgehog receptor Patched (Ptch1) is overexpressed in many types of cancers. We showed that Ptch1 contributes to the efflux of doxorubicin and plays an important role in the resistance to chemotherapy in adrenocortical carcinoma (ACC), a rare cancer which presents strong resistance to the standard of care chemotherapy treatment. In the present study, we isolated and characterized a subpopulation of the ACC cell line H295R in which Ptch1 is overexpressed and more present at the cell surface. This cell subpopulation is more resistant to doxorubicin, grows as spheroids, and has a greater capability of clonogenicity, migration, and invasion than the parental cells. Xenograft experiments performed in mice and in ovo showed that this cell subpopulation is more tumorigenic and metastatic than the parental cells. These results suggest that this cell subpopulation has cancer stem-like or persistent cell properties which were strengthened by RNA-seq. If present in tumors from ACC patients, these cells could be responsible for therapy resistance, relapse, and metastases.Entities:
Keywords: Patched; adrenocortical carcinoma; cancer stem cells; chemotherapy resistance; metastases; persistent cells
Year: 2022 PMID: 35631574 PMCID: PMC9146430 DOI: 10.3390/pharmaceutics14050988
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.525
Figure 1A small population of ACC cells H295R overexpresses Ptch1 at the plasma membrane. (A) H295R were labeled with an anti-Ptch1 antibody directed against the extracellular loop and cells presenting Ptch1 at their plasma membrane (H295R-PM-Ptc+ AF594+ cells) were sorted. AF594+ in blue represents the percentage of cells with Ptch1 at the cell surface (H295R-PM-Ptc+ cells). (B) Surface labeling of Ptch1 using anti-Ptch1 antibody directed against the extracellular loop of Ptch1 (Alexa 594 in red) on nonpermeabilized parental H295R and H295R-PM-Ptc+ cells. Nuclei were stained with DAPI (in blue). The histogram represents the mean ± SEM of Alexa 594 fluorescence intensity per cell (****: p-value < 0.00005 (p-value = 2 × 10−36)).
Figure 2H295R-PM-Ptc+ cells are more resistant to chemotherapy than parental cells. (A) Doxorubicin (dxr) cytotoxicity. H295R and H295R-PM-Ptc+ cells were treated for 48 h with increasing concentrations of dxr before cell viability measure. (B) Doxorubicin IC50 of H295R-PM-Ptc+ and H295R parental cells in the absence or the presence of 10 μM of the Ptch1 efflux inhibitor methiothepin. (C) H295R-PM-Ptc+ cells accumulate less doxorubicin than parental H295R cells. Cells on coverslips were incubated with 2 μM dxr for 15, 30, 60, 180 and 240 min and immediately fixed with PFA. Dxr fluorescence was acquired using a filter for Alexa 594 and quantified using ImageJ software. About 100 cells (from three wells) were scored per condition per experiment. All data presented are the mean ± SEM of at least 3 independent experiments. Significance is attained at p-value < 0.05 (*), (**** p < 0.00005).
Figure 3H295R PM-Ptc+ cells are more aggressive than parental H295R cells. (A) H295R-PM-Ptc+ cells present a different growth pattern. (B) H295R-PM-Ptc+ show non-significant lower proliferative properties as H295R cells over 72 h (n = 3; no significant difference (ns)). (C) H295R-PM-Ptc+ cells form more clones than ACC cells 14 days after seeding 5000 cells/well. Histogram represents the quantification of clones formed using crystal violet for 3 independent experiments (p = 0.003). A representative image of clones stained with crystal violet is provided for each cell group. (D) H295R-PM-Ptc+ cells migrate faster than H295R cells. Migration ability of the two cell groups was evaluated using wound healing experiment. Slope of migration for 24 h, normalized to H295R, n = 5, (p = 0.005). H295R-PM-Ptc+ cells completely reclose the wound compared to H295R cells, images taken 12 and 20 days after producing the wound (5× objective, scale = 100 µm). (E) H295R-PM-Ptc+ cells are more invasive than parental cells. More H295R-PM-Ptc+ cells were able to pass through Matrigel-coated filters compared to H295R. Invasion was normalized to H295R and proliferation differences, cells passed through the filter were counted and reported to the total cell number (n = 2). All data presented are the mean ± SEM of independent experiments. **: p-value < 0.005, ***: p-value < 0.0005.
Figure 4H295R-PM-Ptc+ cells are more tumorigenic than parental cells in mice. Each mouse received a renal subcapsular injection of H295R PM-Ptc+ or parental H295R cells (3 × 106 cells; 10 mice for each cell group). After 45 days, mice were sacrificed, tumors were collected, weighed and fixed. (A) The mean weight of H295R-PM-Ptc+ tumors is significantly higher than H295R tumors (n = 9; *: p-value < 0.05 (p = 0.018)). (B) KI67 immunostaining on tumor slices. KI67 is marked with anti-human KI67 antibody recognized with a secondary antibody coupled to Alexa 488 (green staining) and DAPI (blue staining). Images were taken with an epifluorescence microscope (40×). (C) Tumors derived from H295R-PM-Ptc+ cells present bigger nuclei compared to tumors from parental cells. For each tumor, 20 nuclei diameters were measured (SRC-sample randomly chosen) from slides using imageJ software. Six H295R tumors and seven H295R PM-PTC+ tumors (*: p-value < 0.005).
Figure 5H295R-PM-Ptc+ cells are more tumorigenic and metastatic than parental ACC cells in ovo. (A) Schematic representation of the study. On day 9 of egg development (E9) 3 × 106 H295R-PM-Ptc+ and H295R cells were injected in the chorioallantoic membrane (CAM) from two groups of 20 eggs. At E18 tumors from CAM and embryos were collected. (B) H295R-PM-Ptc tumors collected on E18 were bigger than H295R tumors (n = 15 for H295R graft and n = 21 for H295R-PM-Ptc+; ****: p-value < 0.00005). (C) Metastasis in liver was addressed using human Alu sequences by real time qPCR. H295R-PM-Ptc+ xenografted cells form more metastases in the embryo liver compared to H295R xenografted cells (mean ± SEM n = 9, *: p-value < 0.05 (p = 0.03)).
Differentially expressed genes (DEG) between H295R-PM-Ptc+ and parental H295R cells selected for their role in cancer. Genes overexpressed are indicated in red and genes underexpressed are in blue.
| GDE | H295R-PMPtc+/H295R Log2 | Role in Cancer | |
|---|---|---|---|
|
| |||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| −0.427 |
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
| |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Figure 6Heat map of differentially expressed genes (DEG) between H295R-PM-Ptc+ and parental H295R cells of interest for their role in cancer.
Figure 7Network of protein–protein interactions between the members of the active modules containing one or more of the identified genes of interest listed in Table 1. The nodes on the network correspond to genes. Node colors represent the log2 fold change values of the corresponding gene on a scale varying from blue (for the most underexpressed genes) to red (for the most overexpressed genes). Edges correspond to interactions reported in the String database with a combined evidence score ≥0.4. Each module is identified by its number (specified in Supplementary MaterialsTables S2 and S3). The complete lists of the enrichments of all the modules are shown in Supplementary Materials Table S4.
Composition of active modules containing one or more of the identified genes of interest listed in Table 1 (in bold) with genes upregulated in red and genes downregulated in blue, representative enrichment and role of differentially expressed genes (DEGs) in cancers.
| Module Number and Composition | Representative Enrichment | Role of the DEGs in Cancer |
|---|---|---|
| Extracellular matrix organization | CSC maintenance, EMT | |
|
| Vesicle transport, cell adhesion | Cancer development and progression, poorer prognosis |
|
| Signaling by GPCR | Regulation of CSC, cancer cell survival, metastasis, poor prognosis |
| Regulation of cell population proliferation | Maintenance of mesenchymal phenotype, invasive migration, metastasis, poor prognosis, chemotherapy resistance | |
| Platelet degranulation | EMT induction and metastasis | |
| Hedgehog signaling, cell differentiation, cell fate specification, development | Hedgehog pathway activation, CSC maintenance, tumor cell survival | |
|
| RET signaling | Stem cell self-renewal |
|
| Retinoic acid metabolic process | Chemotherapy resistance, CSC, poor prognosis |
| Endosome membrane, endocytosis | Membrane trafficking, endocytosis, cancer cell motility and invasiveness, cancer development and progression, metastasis | |
|
| Negative regulation of differentiation | Poor patient survival, malignant phenotype and metastasis, tumor progression and development, cell proliferation, migration and EMT |
|
| Endocytosis, membrane trafficking | Proliferation, migration and invasion, cancer progression and metastasis, poor prognosis |
|
| Transcription factors, cell-cycle progression | CSC maintenance, EMT, invasion, metastasis |
|
| G protein-coupled receptor activity | Stem cell maintenance |
| Cell–cell adhesion | EMT, cell migration and invasion, poor prognosis | |
|
| Sphingolipid metabolism | Multidrug resistance, proliferation of cancer cells, cell migration and metastasis |
|
| Melanoma phenotype switching | Enrichment of stem cells, de-differentiated state and invasiveness |
|
| Mitochondrial respiratory chain complex | Malignant behavior of cancer cells, cell cycle progression |
|
| SLC-mediated transmembrane transport | Cell proliferation, epithelial-to-mesenchymal transition |
Figure 8Protein expression of some differentially expressed genes between H295R cells parental and H295R PM-Ptc+ cells FACS sorted and amplified. Western blots were performed using anti-DEG antibodies, and β-tubulin or GAPDH antibodies for the loading control. Signals on Western blots were quantified using ImageJ software. Data presented are the mean ± SEM of at least 3 independent experiments. p-values were calculated using Student’s t-test.